Yes the ops move gives less risk to the sp, and makes the company more attractive as a T/O also makes it more attractive to Board purchasing stock prior to an announcement!
Trial results have had a high degree of variability thats very true and have bee done on to small a sample IMHO but the nano market cap is small for a company at this stage of devpt
They should not worry about FDA approval instead go the European route dueto the plant based product liked by German pharmacies
I would be hesitant about holding too much in this as it is extremely speculative so many wonder cancer treatment companies out there!
- Forums
- ASX - By Stock
- agm today
SBP
solbec pharmaceuticals limited
Yes the ops move gives less risk to the sp, and makes the...
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online